Dienogest use and the risk of breast and gynecologic cancers: A nationwide population-based study.

ABSTRACT:

Objective

To evaluate whether dienogest exposure is associated with the risk of breast, endometrial, or tubo-ovarian cancer in women with endometriosis.

Methods

In this nationwide retrospective cohort study (January 2012 to December 2023), we used the Korean National Health Insurance Review & Assessment Service database. Women aged 20-49 years with endometriosis who received dienogest for at least 6 months were compared with an active control group treated with gonadotropin-releasing hormone (GnRH) agonists, with cohorts balanced by inverse probability of treatment weighting. Incident breast, endometrial, and tubo-ovarian cancers were ascertained, and adjusted hazard ratios (aHR) were estimated using Cox proportional hazards models.

Results

Among 1 887 957 women with

SUBMITTER: Jhang H 

PROVIDER: S-EPMC12790670 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature